CIALIS Drug Patent Profile

Which patents cover Cialis, and when can generic versions of Cialis launch?

Cialis is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in CIALIS is tadalafil. There are twenty-five drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the tadalafil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cialis

A generic version of CIALIS was approved as tadalafil by TEVA PHARMS USA on May 22^nd, 2018.

Summary for CIALIS

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	95
Patent Applications:	7,070
Drug Prices:	Drug price information for CIALIS
Drug Sales Revenues:	Drug sales revenues for CIALIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CIALIS
What excipients (inactive ingredients) are in CIALIS?	CIALIS excipients list
DailyMed Link:	CIALIS at DailyMed

See drug prices for CIALIS

See drug sales revenues for CIALIS

Recent Clinical Trials for CIALIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Arizona	Phase 2
University of Florida	Phase 2/Phase 3
Dongkook Pharmaceutical Co., Ltd.	Phase 3

See all CIALIS clinical trials

Pharmacology for CIALIS

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Paragraph IV (Patent) Challenges for CIALIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CIALIS	Tablets	tadalafil	2.5 mg	021368	1	2008-10-14
CIALIS	Tablets	tadalafil	5 mg, 10 mg and 20 mg	021368	1	2007-11-21

US Patents and Regulatory Information for CIALIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-004	Jan 7, 2008		DISCN	Yes	No
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-003	Nov 21, 2003	AB1	RX	Yes	Yes
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-001	Nov 21, 2003	AB1	RX	Yes	No
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-002	Nov 21, 2003	AB1	RX	Yes	No

Expired US Patents for CIALIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-003	Nov 21, 2003
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-004	Jan 7, 2008
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-002	Nov 21, 2003
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-001	Nov 21, 2003

EU/EMA Drug Approvals for CIALIS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Limited	Talmanco (previously Tadalafil Generics)	tadalafil	EMEA/H/C/004297Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.	Authorised	yes	no	no	2017-01-09
Eli Lilly Nederland B.V.	Tadalafil Lilly	tadalafil	EMEA/H/C/004666Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Lilly is not indicated for use by women.Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.	Authorised	no	no	no	2017-03-22
Eli Lilly Nederland B.V.	Adcirca (previously Tadalafil Lilly)	tadalafil	EMEA/H/C/001021AdultsTreatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1).Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.Paediatric populationTreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III.	Authorised	no	no	no	2008-10-01
Eli Lilly Nederland B.V.	Cialis	tadalafil	EMEA/H/C/000436Treatment of erectile dysfunction.In order for tadalafil to be effective, sexual stimulation is required.Cialis is not indicated for use by women.	Authorised	no	no	no	2002-11-12

International Patents for CIALIS

See the table below for patents covering CIALIS around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	556	Tetracyclic derivatives, process of preparation and use.
African Regional IP Organization (ARIPO)	9500712
Argentina	003455	DERIVADOS TETRACICLICOS, SU USO EN LA PREPARACION DE UN MEDICAMENTO, UN METODO DE TRATAMIENTO, UNA COMPOSICION FARMACEUTICA Y PROCESOS PARA LAPREPARACION DE UNA COMPOSICION FARMACEUTICA Y PARA PREPARAR LOS COMPUESTOS.
Austria	169018

Supplementary Protection Certificates for CIALIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0740668	SPC004/2003	Ireland		SPC004/2003, 20040610, EXPIRES: 20171111
0740668	91017	Luxembourg
0740668	PA2003001	Lithuania		PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
0740668	300124	Netherlands		300124, 20150119, EXPIRES: 20171111

CIALIS (tadalafil) market dynamics and financial trajectory: revenue drivers, competition, exclusivity timelines, and generic/biosimilar risks

Last updated: June 15, 2026

Executive summary

• CIALIS (tadalafil) is an oral phosphodiesterase-5 (PDE5) inhibitor for erectile dysfunction (ED), with FDA market authorization across multiple dose strengths and once-daily regimens (notably 2.5 mg and 5 mg) plus on-demand dosing (10 mg/20 mg).
• Commercial growth has been driven by dosing convenience and persistence of ED patient demand, with later-cycle leverage from expanding once-daily adoption and label-based flexibility across comorbid populations.
• The major long-term market dynamic is price erosion after patent and exclusivity expiry, followed by high-intensity generic competition in the US and other markets, reducing brand unit economics and compressing prescription reimbursement.
• Financial trajectory is dominated by (1) US brand sales durability into the first waves of generics, (2) ability to defend higher-margin channels via formulary positioning, and (3) incremental international share shifts where patent-to-generic timing differed by geography.

What drives CIALIS revenue dynamics in erectile dysfunction: once-daily vs on-demand, dosing adherence, and payer mix?

Short answer: Once-daily tadalafil regimens and prescriber adoption patterns materially shape CIALIS unit demand and brand resilience, with payer formularies and step-therapy policies determining share between branded and generic PDE5 inhibitors.

Why dosing form matters: patient behavior and prescribing patterns

• PDE5 inhibitors compete on onset profile, tolerability, and convenience. For tadalafil, the clinical differentiation has historically supported:
  • Longer duration of effect relative to several comparator PDE5 inhibitors, improving “planning-free” use for some patients.
  • A once-daily option that can convert “episodic” users into more continuous users, raising prescription frequency and improving persistence.

Commercial levers

• Formulary placement and tier position. Brand profitability depends on being placed favorably (preferred tier) or at least avoiding aggressive step-editing early in brand life. Over time, many payers shift preferred status to lower-cost generics.
• Channel mix (retail vs mail order). When generics enter, mail order often accelerates cost-driven switching.
• Segment targeting. ED treatment is sensitive to age distribution, cardiometabolic prevalence, and access to primary care vs urology specialty care.

When does CIALIS lose exclusivity in the US: patent expiry, FDA exclusivity, and generic entry timing?

Short answer: Generic entry risk is tied to the expiration of the Orange Book-listed patents for tadalafil and any applicable exclusivity periods; after those milestones, Paragraph IV and non-Paragraph IV ANDA pathways can lead to launch and price compression.

How exclusivity typically affects tadalafil competition

• Orange Book patents govern ANDA non-exclusivity access. Once product patents and key formulation/method-of-use patents expire, generic firms can file and, if already approved, launch promptly after any regulatory barriers clear.
• FDA exclusivity is usually time-limited and specific to regulatory submissions. For small-molecule brands, exclusivity typically does not extend beyond patent life in a way that prevents generics once core patents expire.

Practical market impact after expiry

• Expect a phased commercial transition:
  • Initial price drop once multiple generics launch.
  • Additional margin erosion when larger wholesalers gain greater dispensing penetration and when payers formalize generic-only coverage.

What patents protect CIALIS (tadalafil) and how do they shape generic launch risk?

Short answer: CIALIS’s long patent tail (covering active ingredient, compositions, and dosing/regimen-related claims) has historically constrained direct ANDA launch until expiry. Generic risk concentrates around the Orange Book “core” patents and any additional claims that remain enforceable.

Patent estate components that matter to launch timing

• Composition of matter patents covering tadalafil itself and/or specific crystalline forms or salts (if claimed).
• Formulation patents covering tablets, excipients, and release characteristics.
• Method-of-use patents sometimes covering dosing regimens (not always central for small molecules, but relevant if remaining claims are enforceable).
• Dosing/regimen claims that can be asserted to delay “skinny labeling” design-arounds.

Litigation and Paragraph IV pressure points

• The commercial threat escalates when:
  • Multiple ANDA filings are pending on the same Orange Book-listed patents.
  • The brand faces adverse district court rulings or unfavorable settlements that allow earlier-than-expected launch.

How many generic versions of tadalafil typically enter after CIALIS: ANDA landscape and price erosion curve?

Short answer: After major patent expiry, tadalafil generics usually exhibit rapid multi-firm entry, which drives steep initial price declines followed by smaller incremental reductions.

What to expect in the price and share trajectory

• Early post-launch phase (first 6–12 months):
  • Brand share falls quickly as payers update formularies.
  • Wholesale acquisition cost (WAC) declines; retail prices follow, driven by competitive bidding and PBM contracting.
• Stabilization phase (12–24 months):
  • Further erosion narrows as market share concentrates among the most cost-efficient manufacturers.
• Long-tail phase (24+ months):
  • Continued price competition, fewer high-cost skus, and stronger generic brand parity via marketing of dosage strengths.

Which product features move demand between brands and generics

• Once-daily dosing often remains a key driver of “stickiness” even after generics enter, because prescriber and patient routines reduce switching friction.

What formulation and dosing patents for tadalafil affect design-arounds?

Short answer: Generic manufacturers focus on avoiding claim infringement for tablet compositions, release profiles, and any claimed manufacturing method features that are still active in relevant jurisdictions.

Key design-around categories

• Excipients and tablet composition differences that attempt to avoid literal infringement.
• Manufacturing process variations for granulation, blending, compression, and coating steps if process patents remain enforceable.
• Crystalline form or solid-state differences if those are claimed and protected.
• Labeling and regimen: when method-of-use or regimen claims exist, generics attempt to use “skinny labeling” that excludes the protected instruction set.

What Orange Book status does CIALIS have today: how to interpret listings for enforcement risk?

Short answer: Current Orange Book status determines what patents remain listed and which expiration dates control ANDA entry risk. If major patents have expired, generics can typically launch without needing paragraph IV litigation.

How to read the Orange Book in commercial terms

• Patent term (expiration date) sets the earliest non-patent-delayed launch window.
• Patent type matters:
  • Composition of matter generally blocks most straightforward ANDA launch.
  • Method-of-use and formulation patents can still delay “surgical” label or formulation launch if not avoided.
• Remaining “unexpired” patents at the time of ANDA submission determine litigation likelihood.

What patent litigation affects CIALIS: cases, settlements, and timing outcomes?

Short answer: The major litigation pattern for established small-molecule brands like tadalafil involves Paragraph IV challenges to Orange Book-listed patents, with settlements often defining launch carve-outs or agreed-entry dates.

Settlement-driven entry scenarios

• Brand settlements frequently create:
  • Agreed effective launch dates that fall between initial expiry and full enforcement end.
  • Licensed entries where generics receive time-limited market access.
  • Design-around covenants that restrict generic labeling or product features.

Why litigation history matters for financial trajectory

• Settlements can blunt early generic uptake, preserving brand revenue longer.
• Adverse outcomes (invalidation or non-infringement rulings) can accelerate price erosion, pulling down financial results.

How does CIALIS compare with other PDE5 inhibitors (Viagra, Levitra, Stendra) on commercialization and competitive intensity?

Short answer: The PDE5 inhibitor class shares payer and prescribing infrastructure, so differentiation usually translates into short- to mid-cycle market share advantages. When generics arrive, competition intensifies across the whole class, shifting economics toward lowest net cost.

Competitive dynamics by mechanism-of-entry

• During brand life: CIALIS benefits from differentiation on duration and dosing convenience.
• After generic entry: competition converges to price, formulary placement, and PBM rebate structures.
• Across dosing regimens: once-daily tadalafil competes most directly with any alternate “convenience dosing” strategies in the category, while on-demand regimens compete on onset and tolerability.

What is the biosimilar risk for CIALIS?

Short answer: No biosimilar pathway applies to CIALIS because tadalafil is a small molecule, not a biologic.

Implication for investors and business planning

• The competitive substitution framework is generic ANDAs and authorized generics, not biosimilar entrants.

What manufacturing and IP barriers can delay generic tadalafil launches?

Short answer: Generic launch risk is mainly legal and regulatory rather than manufacturing. Practical barriers arise from quality systems, bioequivalence testing scale, and any remaining enforceable IP tied to solid-state or formulation.

Typical operational gating points

• Bioequivalence studies and comparative dissolution performance for each dosage strength.
• Solid-state controls if any crystalline form or tablet performance characteristics are scrutinized.
• Regulatory readiness at launch scale for 2.5 mg/5 mg/10 mg/20 mg strengths.

What is the commercial trajectory for CIALIS revenue after generic entry: typical outcomes for mature small-molecule brands?

Short answer: Mature small-molecule brands usually show steep revenue decline after multiple generic entries, followed by limited stabilization tied to remaining brand differentiation, channel contracts, and supply continuity.

Revenue decomposition framework

• Volume: rapidly erodes post-generic launch as payers switch to lower-cost options.
• Net price: collapses with competitive tendering and rebate rebalancing.
• Mix: branded vs generic mix becomes the dominant driver; brand often retains a smaller premium base where clinicians and patients prefer the branded product or specific regimen.

Channel and payer behavior

• PBMs generally move quickly once at least one low-cost generic is available for the relevant strengths.
• Hospital and specialty channels are less relevant for ED than retail/mass markets, so dispensing economics dominate.

What international dynamics matter for CIALIS: geography-specific patent cliffs and pricing controls?

Short answer: International revenue performance depends on local patent status and reimbursement controls. Many markets introduce generics quickly after patent expiry, but the timing varies by jurisdiction.

Market-specific forces

• Patent enforcement strength and duration in each country.
• Regulatory approval speed for generics after local expiry.
• National reimbursement rules that can accelerate substitution independent of brand switching behavior.

Key Takeaways

• CIALIS’s market dynamics center on tadalafil’s dosing convenience, particularly once-daily use, which influences persistence and prescription frequency.
• Exclusivity and Orange Book-listed patent expiry set the schedule for generic pressure. After expiry, tadalafil generics typically enter rapidly, causing price and share erosion.
• There is no biosimilar competition risk for CIALIS because tadalafil is a small molecule; the substitution risk is ANDA/generic entry.
• Financial trajectory post-generic entry typically follows a steep decline in revenue from mix and net price compression, with partial stabilization only where brand differentiation and contracting preserve small premium demand.

FAQs

1. Does once-daily tadalafil retain more brand share after generic entry than on-demand dosing?
2. How do Paragraph IV settlements usually affect the timing of tadalafil generic launches?
3. Which Orange Book patent types most often delay ANDA approval for tadalafil tablets?
4. What labeling strategy do tadalafil generics use to navigate method-of-use or regimen patents?
5. How quickly do PBMs switch from brand CIALIS to generic tadalafil after patent expiry?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
2. FDA. Abbreviated New Drug Applications (ANDA). U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
3. FDA. Generic Drug Development: Bioequivalence. U.S. Food and Drug Administration. https://www.fda.gov/drugs/generic-drugs/generic-drug-approvals-and-supplements

DrugChatter Q&A for CIALIS

U's pharmacy prices for cialis?
U's pharmacy prices for cialis?
What is the cost of cialis?
U's pharmacy prices for cialis?
U's pharmacy prices for cialis?